-
IAS 2023 | Joining Hands to Eliminate AIDS Epidemic by 2030
On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized…
-
ESMO ASIA 2023 opens, and CSCO accepts certificate of appreciation
ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity…
-
ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence
At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition,…
-
ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival
Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. “Oncology Frontier” has…
-
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients
Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT…
-
Expert Insight | Dr. Guangxin Li: Latest Clinical Research Progress on Radiotherapy Combined with Immunotherapy for Liver Cancer
As early as 2017, when immunotherapy was just introduced for the treatment of liver cancer, Korean scholars began clinical trials of combining radiotherapy with immunotherapy. In a clinical study published…
-
Dr. Guohong Han: Combining Targeted Therapy to Reduce Postoperative Liver Cancer Recurrence and Prolong Survival in Cirrhotic Patients with Anticoagulation
Hepatology Digest: Liver cancer immunotherapy has been a major focus of this year’s conference, particularly the research presented on June 23rd regarding adjuvant targeted immunotherapy for high-risk liver cancer recurrence…
-
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections
Chronic hepatitis B (CHB) remains a global medical burden. According to the guidelines released by the European Association for the Study of the Liver (EASL) in 2017, the natural history…
Connecting Medical Expertise through Media